Shares of Corbus Pharmaceuticals Holdings Inc. CRBP slipped 5.31% to $14.28 Monday, on what proved to be an all-around mixed ...

Corbus Pharmaceuticals Holdings Inc. closed $46.82 short of its 52-week high ($61.90), which the company achieved on July ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on CRBP stock, giving a Buy rating on December 2.Pick the best ...

CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environmentNORWOOD ...

We recently compiled a list of the 10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. In this ...

Corbus Pharmaceuticals (CRBP) announced the dosing of the first patient in the Phase 1 portion of the clinical study of CRB-601 for the ...

Fintel reports that on December 2, 2024, Piper Sandler initiated coverage of Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) ...

Corbus Pharmaceuticals (NASDAQ:CRBP) Holdings Inc (NASDAQ:CRBP) has emerged as a promising player in the biopharmaceutical sector, focusing on developing novel therapeutics for cancer and obesity.

Piper Sandler started coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research note released on ...

Corbus Pharmaceuticals (CRBP) announced the dosing of the first patient in the Phase 1 portion of the clinical study of CRB-601 for the treatment of patients with advanced solid tumors.

Corbus Pharmaceuticals Holdings, Inc. has a 1-year low of $4.94 and a 1-year high of $61.90. The business has a fifty day moving average price of $17.69 and a 200-day moving average price of $38. ...

Corbus Pharmaceuticals has successfully reinvented itself with a portfolio of assets targeting validated approaches in drug development. The company's pipeline includes three main candidates: CRB-701, ...